본문 바로가기
KERD
논문KCI 등재

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Donghee Kim|Aijaz Ahmed|Peter Konyn
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 43-57

2

조회

0

다운로드

11

인용

0

참고문헌

키워드

Risk factorDeathOutcomeNASHNon-alcoholic fatty liver disease and fatty liver

초록

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.

참고문헌 (76)

  1. Murag Soumya, "Recent Epidemiology of Nonalcoholic Fatty Liver Disease", Gut and Liver, 15(2), pp.206~216 (2021), 거트앤리버 소화기연관학회협의회[DOI]
  2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
  3. Yoo ER, "Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality", Liver Int, 40, pp.815~824 (2020)
  4. Andrew A. Li, "Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Gut and Liver, 14(2), pp.168~178 (2020), 거트앤리버 소화기연관학회협의회
  5. Konyn P, "Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality", Clin Gastroenterol Hepatol (2022)[DOI]
  6. Kim D, "Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017-2018", Clin Gastroenterol Hepatol, 19, pp.1499~1501 (2021)
  7. Kim D, "Race", ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016, 2019, pp.13, 205~213
  8. Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
  9. Kim D, "Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016", Gastroenterology, 155, pp.1154~1163 (2018)
  10. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
  11. Kim D, "Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017", Gastroenterology, 157, pp.1055~1066 (2019)
  12. Kim D, "Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States", Hepatology, 57, pp.1357~1365 (2013)
  13. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
  14. Cheng Han Ng, "Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name", Clinical and Molecular Hepatology, 28(4), pp.790~801 (2022), 대한간학회
  15. Adams LA, "The natural history of nonalcoholic fatty liver disease : a population-based cohort study", Gastroenterology, 129, pp.113~121 (2005)
  16. Kwak MS, "Long-term outcomes of nonalcoholic fatty liver disease", Curr hepat0 rep, 14, pp.69~76 (2015)
  17. Kim D, "Nonalcoholic fatty liver disease in early life and all-cause and cause-specific mortality", Hepatobiliary Surg Nutr, 11, pp.317~319 (2022)
  18. Ruhl CE, "Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population", Gastroenterology, 136, pp.477~485 (2009)
  19. Dam-Larsen S, "Long term prognosis of fatty liver : risk of chronic liver disease and death", Gut, 53, pp.750~755 (2004)
  20. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
  21. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
  22. Alvarez CS, "Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States : results from the third national health and nutrition examination survey with 27 years of follow-up", Hepatology, 72, pp.430~440 (2020)
  23. Mantovani A, "Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events : an updated systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.903~913 (2021)
  24. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : a multi-national cohort study", Gastroenterology, 155, pp.443~457 (2018)
  25. Kim GA, "Association between non-alcoholic fatty liver disease and cancer incidence rate", J Hepatol, 68, pp.140~146 (2018)
  26. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity-a longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
  27. Huber Y, "Tumor incidence in patients with non-alcoholic fatty liver disease", Dtsch Arztebl Int, 117, pp.719~724 (2020)
  28. Mantovani A, "Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers : a meta-analysis of observational cohort studies", Gut, 71, pp.778~788 (2022)
  29. Gehrke N, "Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease?", Gastroenterology, 158, pp.1929~1947 (2020)
  30. Sheka AC, "Nonalcoholic steatohepatitis : a review", JAMA, 323, pp.1175~1183 (2020)
  31. Kasper P, "NAFLD and cardiovascular diseases : a clinical review", Clin Res Cardiol, 110, pp.921~937 (2021)
  32. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
  33. Kim D, "Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States", Hepatology, 69, pp.1064~1074 (2019)
  34. Ioannou GN, "Epidemiology and risk-stratification of NAFLDassociated HCC", J Hepatol, 75, pp.1476~1484 (2021)
  35. Hwang Sik Shin, "Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases", Clinical and Molecular Hepatology, 28(4), pp.773~789 (2022), 대한간학회
  36. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  37. Younossi ZM, "Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
  38. Konyn P, "Current epidemiology in hepatocellular carcinoma", Expert Rev Gastroenterol Hepatol, 15, pp.1295~1307 (2021)
  39. Global Burden of Disease Cancer Collaboration, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015 : a systematic analysis for the global burden of disease study", JAMA Oncol, 3, pp.524~548 (2017)
  40. GBD 2013 Mortality and Causes of Death Collaborators, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013 : a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 385, pp.117~171 (2015)
  41. Kim D, "Decline in annual mortality of hepatitis C virus-related hepatocellular carcinoma in the United States, from 2009 to 2018", Gastroenterology, 159, pp.1558~1560 (2020)
  42. Wang L, "Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999-2018", JAMA, 326, pp.1~13 (2021)
  43. Kim D, "Nonalcoholic fatty liver disease and metabolic syndrome", Clin Liver Dis, 22, pp.133~140 (2018)
  44. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : a systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
  45. Kim D, "Prevalence of nonalcoholic fatty liver disease and hepatic fibrosis among US Adults with prediabetes and diabetes, NHANES 2017-2018", J Gen Intern Med, 37, pp.261~263 (2022)
  46. Kim D, "Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017", Diabetologia, 62, pp.1185~1194 (2019)
  47. Kim D, "Increasing mortality among patients with diabetes and chronic liver disease from 2007 to 2017", Clin Gastroenterol Hepatol, 18, pp.992~994 (2020)
  48. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
  49. Yoo ER, "Genetic factors and continental ancestry account for some disparities in nonalcoholic fatty liver disease among hispanic subgroups", Clin Gastroenterol Hepatol, 17, pp.2176~2178 (2019)
  50. Walker RW, "A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank", J Hepatol, 72, pp.1070~1081 (2020)
  51. Meffert PJ, "The PNPLA3 SNP rs738409 : G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort", J Hepatol, 68, pp.858~860 (2018)
  52. Simons N, "PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease", Gastroenterology, 152, pp.912~913 (2017)
  53. Wijarnpreecha K, "PNPLA3 gene polymorphism and overall and cardiovascular mortality in the United States", J Gastroenterol Hepatol, 35, pp.1789~1794 (2020)
  54. Wijarnpreecha K, "PNPLA3 gene polymorphism and liver-and extrahepatic cancer-related mortality in the United States", Clin Gastroenterol Hepatol, 19, pp.1064~1066 (2021)
  55. Xia M, "NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population : the Shanghai Changfeng Study", Aliment Pharmacol Ther, 55, pp.705~721 (2022)
  56. Chung GE, "Nonalcoholic fatty liver disease across the spectrum of hypothyroidism", J Hepatol, 57, pp.150~156 (2012)
  57. Kim D, "Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis", Clin Gastroenterol Hepatol, 16, pp.123~131 (2018)
  58. Kim D, "Low-normal thyroid function is associated with advanced fibrosis among adults in the United States", Clin Gastroenterol Hepatol, 17, pp.2379~2381 (2019)
  59. Chung GE, "Longitudinal change in thyroid-stimulating hormone and risk of nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 19, pp.848~849 (2021)
  60. Kim D, "Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality", Am J Gastroenterol, 115, pp.1496~1504 (2020)
  61. Kuchay MS, "Non-alcoholic fatty liver disease-related fibrosis and sarcopenia : an altered liver-muscle crosstalk leading to increased mortality risk", Ageing Res Rev, 80, pp.101696~ (2022)
  62. Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : the Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
  63. Lee YH, "Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance : nationwide surveys(KNHANES 2008-2011)", J Hepatol, 63, pp.486~493 (2015)
  64. Koo BK, "Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis", J Hepatol, 66, pp.123~131 (2017)
  65. Wijarnpreecha K, "Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA", Eur J Gastroenterol Hepatol, 31, pp.1121~1128 (2019)
  66. Kim D, "Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States", Liver Int, 41, pp.1832~1840 (2021)
  67. Moon JH, "Non-alcoholic fatty liver disease and sarcopenia additively increase mortality : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 12, pp.964~972 (2021)
  68. Golabi P, "Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease", JHEP Rep, 2, pp.100171~ (2020)
  69. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American association for the study of liver diseases", Hepatology, 67, pp.328~357 (2018)
  70. Younossi ZM, "AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease : expert review", Gastroenterology, 160, pp.912~918 (2021)
  71. Kistler KD, "Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease", Am J Gastroenterol, 106, pp.460~468 (2011)
  72. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
  73. Piercy KL, "The physical activity guidelines for Americans", JAMA, 320, pp.2020~2028 (2018)
  74. Kim D, "Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease", Hepatology, 72, pp.1556~1568 (2020)
  75. Kim D, "Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by fibroScan", Clin Gastroenterol Hepatol, 20, pp.e1438~e1455 (2022)
  76. Kim D, "Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 19, pp.1240~1247 (2021)

관련 논문AI추천

Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseAijaz Ahmed, Andrew A. Li, Donghee Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제2호Risk factors in nonalcoholic fatty liver disease전대원, Eileen L. Yoon, Eunji Ko대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseAijaz Ahmed, Donghee Kim, Elizabeth S. Aby, Wijarnpreecha Karn대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Comparison between obese and non-obese nonalcoholic fatty liver diseaseWah-Kheong Chan대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Nonalcoholic fatty liver disease and non-liver comorbiditiesMindie H. Nguyen, Richie Manikat대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Global incidence of adverse clinical events in nonalcoholic fatty liver disease: A systematic review and meta-analysisChristopher D. Stave, David M. Le, Fanpu Ji, Hansen Dang, KeeSeok Lee, Michael H. Le, Mindie H. Nguyen, Ramsey Cheung, Takanori Ito, Thomas C. Baez, Vy H. Nguyen, Yee Hui Yeo, Yuankai Wu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제2호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기